Clinical trials: Oligometastatic Lung Tumor
Triple Negative Breast Cancer, Non Small Cell Lung Cancer
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length of time before participants' disease gets worse.
- Conditions
- Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
- Trial name
- NCT03808337
- Testing
- Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
- Where
- 12 sites in United States
- Volunteers
- 145 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC, Lung Cancer (Diagnosis)
Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site
investigate the molecular differences between primitive lung cancer and the metastatic site.
- Trial name
- NCT07325864
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- European Institute of Oncology
NSCLC Stage IV, Oligometastasis
Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC
In recent years, immune checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1, and programmed death-ligand 1 have achieved milestones in the treatment of NSCLC, from back-line to first-line, and…
- Trial name
- NCT05055583
- Testing
- Toripalimab in Combination With Platinum-based Chemotherapy, Surgical treatment stage, Adjuvant treatment stage
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Carcinoma, Non-Small-Cell Lung
OMEGA, Local Ablative Therapy in Oligometastatic NSCLC
Oligometastatic lung cancer (OM-NSCLC) seems to be associated with a better prognosis than usual Stage IV non-small cell lung cancer when radical local therapy of all metastatic sites is administered but the impact of such an…
- Trial name
- OMEGA (NCT03827577)
- Testing
- Surgical removal of primary and/or of all oligometastases, Non-surgical LAT, Standard medical therapy
- Where
- Italy
- Volunteers
- 195 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Carcinoma, Non-Small-Cell Lung
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients
The purpose of this study is to determine whether chemotherapy combination with local radiotherapy and rhGM-CSF is safe, effective in the treatment of oligometastatic stage IV NSCLC patients.
- Trial name
- CRAGMOLC (NCT03489616)
- Testing
- rhGM-CSF, Pemetrexed, Local Radiotherapy
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Shandong Cancer Hospital and Institute
NSCLC/Oligometastatic Cancer (Single Lung Lesion)
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
This is a phase II, non-randomised study examining the safety of treating high risk centrally located non-small cell lung cancer (NSCLC) tumours and single pulmonary oligometastatic lesions using radiation therapy (RT), for…
- Trial name
- SOURCE Lung (NCT04375904)
- Testing
- Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
- Where
- 2 sites in Ireland
- Volunteers
- 68 people
- Sponsor
- Cancer Trials Ireland
Lung Neoplasms
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
This is a prospective, multicenter, single-arm study on transbronchial microwave ablation using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris…
- Trial name
- NCT05299606
- Testing
- Transbronchial Microwave Ablation
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 12 people
- Sponsor
- Ethicon, Inc.
Non-Small Cell Lung Cancer
Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
This study will investigate the role of sampling suspicious chest lymph nodes with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine…
- Trial name
- NCT04852588
- Testing
- Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA), Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)
- Where
- 2 sites in Canada
- Volunteers
- 29 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-small Cell Lung Cancer
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer
The trial will assess the addition of stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy (SACT) in patients with oligometastatic non-small cell lung cancer.
- Trial name
- SARON (NCT02417662)
- Testing
- Radical Radiotherapy (Conventional RT and SABR), Non-investigational SACT
- Where
- 19 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- University College, London
Non-small Cell Lung Cancer, Oligometastatic Disease
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
A prospective, observational study that assesses the clinical feasibility of ctDNA-based liquid biopsy in patients with oligometastatic NSCLC receiving surgery.
- Trial name
- NCT05648370
- Testing
- ctDNA testing and whole exome sequencing
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital
Non-small Cell Lung Cancer Metastatic
Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer
This study evaluated the effectiveness and safety of Camrelizumab combination with SBRT and concurrent chemotherapy treated stage IV oligometastatic non-small cell lung cancer
- Trial name
- IMCORT-2 (NCT05472467)
- Testing
- Camrelizumab, stereotactic body radiation therapy, Chemotherapy
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Oligometastatic Disease
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2, open-label, multicenter, randomized study comparing the safety and efficacy of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) combined with immune checkpoint inhibitor (ICI) immunotherapy…
- Trial name
- NCT05846646
- Testing
- IMSA101, Immune checkpoint inhibitor, PULSAR
- Where
- 9 sites in United States
- Volunteers
- 6 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
Non Small Cell Lung Cancer
Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease
This is a 2:1 randomized multicentre open label phase III study of radiation combined with standard systemic treatment compared with systemic treatment alone in oligometastatic (≤5 metastases) NSCLC.
- Trial name
- ANDROMEDA (NCT06141070)
- Testing
- Standard systemic therapy + radiotherapy, Standard systemic therapy
- Where
- 6 sites in Sweden
- Volunteers
- 240 people
- Sponsor
- Vastra Gotaland Region
Oligometastatic Lung Tumor, NSCLC (Non-small Cell Lung Cancer)
Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup
Pulmonary tumors, whether primary or metastatic, represent a major challenge in oncology. Primary lung cancers are responsible for nearly 37,000 deaths per year in France, highlighting the critical importance of their management.
- Conditions
- Oligometastatic Lung Tumor, NSCLC (Non-small Cell Lung Cancer), SBRT
- Trial name
- SPARROW (NCT07441941)
- Where
- 2 sites in France
- Volunteers
- 190 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This pilot clinical trial studies stereotactic body radiation therapy after surgery in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01781741
- Testing
- therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Metastasis to Liver
Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer
Investigators designed a phase II study to evaluate safety and efficacy of lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach.
- Conditions
- Breast Cancer, Metastasis to Liver, Metastasis to Lung
- Trial name
- NCT02581670
- Testing
- stereotactic radiation therapy (SRT)
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- Istituto Clinico Humanitas
Non Small Cell Lung Cancer
SBRT/RT in Oligometastatic Stage IV NSCLC
The core hypothesis to be tested is that the use of consolidative SBRT followed by maintenance chemotherapy in patients with less than or equal to 10 metastatic sites will improve progression-free survival (PFS) with acceptable…
- Trial name
- NCT05647590
- Testing
- Chemotherapy, Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT), Maintenance chemotherapy
- Where
- Czechia
- Volunteers
- 10 people
- Sponsor
- University Hospital Ostrava
Stage IV Non-small Cell Lung Cancer
Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.
Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.
- Trial name
- NCT03119519
- Testing
- Local Definitive Radiotherapy, No Local Definitive Radiotherapy
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Southern Medical University, China
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase II, multi-center pilot study assessing the efficacy and safety of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligo-metastatic non-small cell lung cancer…
- Trial name
- NCT04255836
- Testing
- Durvalumab, the first line chemotherapy for metastatic NSCLC, stereotactic body radiotherapy (SBRT)
- Volunteers
- 35 people
- Sponsor
- Zhejiang Cancer Hospital